8-K: OmniAb Q3 2025: Revenue Down, Strategic Initiatives Advance

OmniAb reports Q3 2025 revenue decline and increased net loss, while advancing strategic initiatives and strengthening its balance sheet.

Summary

• Revenue for the third quarter of 2025 was $2.2 million, a decrease from $4.2 million for the same period in 2024.
• Revenue for the nine months ended September 30, 2025, was $10.3 million, down from $15.6 million for the same period in 2024.
• Net loss for the third quarter of 2025 was $16.5 million, or $0.14 per share, compared with a net loss of $16.4 million, or $0.16 per share, for Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $50.6 million, or $0.46 per share, compared with a net loss of $49.0 million, or $0.48 per share, for the same period in 2024.
• Research and development expense decreased to $10.4 million in Q3 2025 from $13.3 million in Q3 2024, and to $33.8 million for 9M 2025 from $41.8 million for 9M 2024.
• General and administrative expense decreased to $6.8 million in Q3 2025 from $7.1 million in Q3 2024, and to $22.4 million for 9M 2025 from $23.4 million for 9M 2024.
• As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $59.5 million.
• OmniAb completed a private placement in August 2025, raising $30 million with net proceeds of approximately $28 million.
• The company now expects 2025 full-year revenue to be in the range of $18 million to $22 million, and operating expense between $82 million and $86 million.
• OmniAb anticipates ending 2025 with cash between $52 million and $56 million.
• The company had 104 active partners and 399 active programs as of September 30, 2025, including 32 OmniAb-derived programs in clinical development or commercialization.
• OmniAb plans to launch its new proprietary discovery platform, OmniUltra, in December 2025.

Sentiment

Score: 5

Explanation: While financial results show a decline in revenue and an increased net loss for the nine-month period, the company has made significant strategic progress, including a successful capital raise that strengthened the balance sheet, a substantial increase in new partner programs, and the upcoming launch of a new proprietary technology (OmniUltra). The reduction in R&D and G&A expenses also indicates efforts towards a leaner cost structure. The mixed financial performance against strategic advancements results in a neutral sentiment.

Positives

• The number of new program additions so far this year has significantly outpaced last year, bolstering the partnered pipeline and creating potential sources of enduring value.
• OmniAb's innovative technology platform and operational model allow for partner and program additions within an increasingly efficient and lean cost structure.
• A private placement completed in August 2025 strengthened the balance sheet, raising $30 million with net proceeds of approximately $28 million.
• The company is expanding its suite of leading-edge technologies, with the upcoming launch of OmniUltra in December 2025, expected to expand the platform and open new business opportunities.
• A U.S. patent related to the new OmniUltra technology, a transgenic chicken producing cow-like antibodies, was issued.
• Partner Immunovant presented positive six-month off-treatment data for batoclimab in uncontrolled Graves disease, with ~80% (17/21) demonstrating response and ~50% (8/17) achieving anti-thyroid drug free remission.
• Immunovant's lead compound IMVT-1402 has two ongoing potentially registrational trials in Graves disease, with topline readouts expected in 2027.
• Arcus Biosciences' anti-TIGIT domvanalimab plus anti-PD-1 zimberelimab and chemotherapy demonstrated 26.7 months of median overall survival in Phase 2 EDGE-Gastric study.
• Shenzhen Salubris Pharmaceuticals' SAL003 New Drug Application was accepted by China's National Medical Products Administration as a Class 1 therapeutic biological.
• Aptevo Therapeutics announced a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial for mipletamig, with no dose-limiting toxicities or cytokine release syndrome observed.
• CStone Pharmaceuticals and Istituto Gentili entered an exclusive partnership to commercialize sugemalimab across 23 countries in Western Europe and the United Kingdom.
• The European Medicines Agency's CHMP issued a positive opinion recommending the approval of sugemalimab for unresectable stage III non-small cell lung cancer.

Negatives

• Revenue for the third quarter of 2025 decreased by 47.6% to $2.2 million from $4.2 million in Q3 2024, primarily due to lower milestone and service revenue.
• Revenue for the nine months ended September 30, 2025, decreased by 34% to $10.3 million from $15.6 million in the same period of 2024, primarily due to lower milestone and service revenue.
• Net loss for the nine months ended September 30, 2025, increased to $50.6 million from $49.0 million in the same period of 2024.
• Service revenue declined primarily as a result of the completion or discontinuation of certain small molecule ion channel programs.

Risks

• Future success is dependent on acceptance of the technology platform and technologies by new and existing partners.
• Success is dependent on the eventual development, approval, and commercialization of products developed by partners, over which the company has no control.
• Biopharmaceutical development is inherently uncertain.
• Risks arise from changes in technology.
• The competitive environment in the life sciences and biotechnology platform market poses challenges.
• Risks associated with quality and timing in manufacturing xPloration instruments and related consumables, and reliance on a limited number of third-party manufacturers and suppliers.
• Failure to maintain, protect, and defend intellectual property rights.
• Difficulties with the performance of third parties the company relies on for its business.
• Government healthcare reform, legislative measures, and regulatory developments in the United States and foreign countries could impact the business.
• Unstable market and economic conditions may have serious adverse consequences on the business, financial condition, and stock price.
• Capital resources may be used sooner than expected.

Future Outlook

OmniAb expects 2025 revenue to be in the range of $18 million to $22 million and operating expenses between $82 million and $86 million. Cash use in 2025 is projected to be lower than in 2024, excluding financings, with an anticipated year-end cash balance between $52 million and $56 million. The company plans to launch its new OmniUltra technology in December 2025, which is expected to expand its platform and open new business opportunities. Partner programs, such as Immunovant's IMVT-1402, have topline readouts expected in 2027.

Management Comments

• "Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering our partnered pipeline and creating potential sources of enduring value within our portfolio." Matt Foehr, Chief Executive Officer of OmniAb.
• "Importantly, OmniAb's innovative technology platform and operational model allow for partner and program additions within an increasingly efficient and lean cost structure." Matt Foehr, Chief Executive Officer of OmniAb.
• "In August we completed a private placement and strengthened our balance sheet while continuing to expand our suite of leading-edge technologies. We look forward to next month's launch of OmniUltra, an important new technology that we expect will expand our platform and open new business opportunities." Matt Foehr, Chief Executive Officer of OmniAb.

Industry Context

OmniAb operates in the highly competitive biotechnology and pharmaceutical industry, specializing in antibody discovery platforms. Its business model, which involves licensing proprietary technology to partners and earning through upfront fees, service revenue, milestones, and royalties, aligns with a trend of specialized technology providers supporting broader drug development efforts. The advancements in partner programs, particularly in areas like autoimmune diseases (Graves disease), oncology (gastroesophageal adenocarcinomas, AML), and metabolic disorders (hypercholesterolemia), reflect ongoing industry focus on these therapeutic areas. The launch of OmniUltra, a new transgenic animal platform, indicates continued innovation in antibody generation technologies, a critical area for next-generation therapeutics.

Comparison to Industry Standards

• The filing states that OmniAb's animals comprise the most diverse host systems available in the industry, and its technologies are leading-edge, but does not provide specific quantitative comparisons to other companies, projects, or industry benchmarks.

Stakeholder Impact

• Shareholders are impacted by declining revenue and increased net loss, but also by the strengthening of the balance sheet through a private placement and the potential for future growth from new technologies and partner programs.
• Employees may be impacted by reduced share-based compensation expense and headcount, which contributed to lower R&D expenses.
• Partners benefit from OmniAb's expanding technology platform (e.g., OmniUltra) and continued support for their drug development efforts, as evidenced by new license agreements and progress in clinical trials.
• Creditors may benefit from the strengthened balance sheet due to the private placement, which could improve the company's financial stability.

Next Steps

• Launch of OmniUltra technology in December 2025 at the Antibody Engineering & Therapeutics (AET) conference in San Diego.
• Conference call with management today (November 4, 2025) at 4:30 p.m. Eastern time to discuss results.
• Continued enrollment in Immunovant's IMVT-1402 registrational trials, with topline readouts expected in 2027.
• Presentation of Rondo Therapeutics' abstract on RNDO-564 at the Society for Immunotherapy of Cancer on November 7, 2025.

Key Dates

Recommendation

The filing presents a mixed picture. While financial performance for Q3 and the nine months ended September 30, 2025, shows a decline in revenue and an increased net loss, strategic initiatives are progressing positively. The company successfully raised $30 million in a private placement, significantly increased new partner programs, and is set to launch a new, potentially impactful technology (OmniUltra). The reduction in operating expenses also indicates a focus on efficiency. However, the financial guidance for 2025 revenue is still relatively low, and profitability remains a challenge. Given the balance of financial headwinds and strategic tailwinds, a "hold" recommendation is appropriate, suggesting investors monitor the successful integration and commercialization of OmniUltra and the progress of partner programs for future catalysts.

Keywords

OmniAb, OABI, biotechnology, antibody discovery, financial results, Q3 2025, platform technology, private placement, OmniUltra, clinical development, drug development, corporate governance, risk management